Apoio Takeda

Apoio Gedii

ECCO 2019 - edifíciosECCO 2019 - data

IBD Horizons

Dominik Bettenworth, Münster, Germany

Janneke N. Samsom, Rotterdam, The Netherlands

OP21: ABX464 is safe and efficacious in a proof of concept study in Ulcerative Colitis patients

OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis

OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates Colitis in various animal models

OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn‘s Disease

OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s Disease

OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn’s Disease: Final results from the GEMINI LTS study

Informação Adicional

  • Data de Início: sexta-feira, 08 março 2019
  • Data de Fim: sexta-feira, 08 março 2019
  • Horário: 15:55-16:55
  • Localidade: Plenary Hall, Hall A, Bella Center

Subscrever Newsletter do Congresso

Agenda

mar06
08:00-14:10
HB4 M1-2, Bella Center
mar06
08:00- 11:30
Auditorium 15, Hall A, Bella Center
mar07
12:15-12:30
Plenary Hall, Hall A, Bella Center
mar07
12:30-14:00
Plenary Hall, Hall A, Bella Center

Área Reservada